COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE

被引：0

作者：

Petropoulos, A. ^{[1
]}

Cooney, P. ^{[2
]}

Patidar, M. ^{[3
]}

Gudala, K. ^{[3
]}

Tiwari, S. ^{[4
]}

Brennan, R. ^{[2
]}

Kapsogeorgiou, K. ^{[1
]}

Cheilas, G. ^{[1
]}

Banhazi, J. ^{[5
]}

机构：

[1] Novartis Hellas SACI, Athens A1, Greece

[2] Novartis Ireland Ltd, Dublin, Ireland

[3] Novartis Healthcare Private Ltd, Hyderabad, India

[4] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India

[5] Novartis Pharma AG, Basel, BS, Switzerland

来源：

VALUE IN HEALTH | 2022年 / 25卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE143

引用

页码：S80 / S81

页数：2

共 50 条

[21] Cost-Effectiveness of Disease-Modifying Therapies for the Treatment of Patients with Highly Active Multiple Sclerosis - Swedish Perspective [J].

O'Day, Ken ;

Deniz, Baris ;

Meyer, Kellie .

NEUROLOGY, 2012, 78

[22] Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies [J].

Iannazzo, Sergio ;

Iliza, Ange-Christelle ;

Perrault, Louise .

PHARMACOECONOMICS, 2018, 36 (02) :189-204

[23] Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies [J].

Sergio Iannazzo ;

Ange-Christelle Iliza ;

Louise Perrault .

PharmacoEconomics, 2018, 36 :189-204

[24] Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis [J].

Parekh, Krupa ;

Watkins, Claire .

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (17) :1265-1266

[25] COST-CONSEQUENCE ANALYSIS OF OFATUMUMAB IN COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA [J].

Farhane, F. ;

Bhan, V ;

Clift, F. ;

Baharnoori, M. ;

Thomas, K. ;

Patel, B. P. ;

Blanchette, F. ;

Adlard, N. E. ;

Vudumula, U. ;

Gudala, K. ;

Dutta, N. ;

Grima, D. ;

Mouallif, S. .

VALUE IN HEALTH, 2022, 25 (12) :S55-S56

[26] Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis [J].

Versteegh, Matthijs M. ;

Huygens, Simone A. ;

Wokke, Beatrijs W. H. ;

Smolders, Joost .

VALUE IN HEALTH, 2022, 25 (06) :984-991

[27] Cost of disease-modifying therapies for multiple sclerosis [J].

Brown, Murray G. .

NEUROLOGY, 2015, 84 (21) :E181-E185

[28] COST-EFFECTIVENESS ANALYSIS OF OFATUMUMAB FOR RELAPSING REMITTING MULTIPLE SCLEROSIS TREATMENT IN ITALY [J].

Antonazzo, I. C. ;

Nica, M. ;

Cortesi, P. ;

Ritrovato, D. ;

Mantovani, L. G. .

VALUE IN HEALTH, 2022, 25 (12) :S342-S343

[29] Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis [J].

Goldberg, Lawrence D. ;

Edwards, Natalie C. ;

Fincher, Contessa ;

Doan, Quan V. ;

Al-Sabbagh, Ahmad ;

Meletiche, Dennis M. .

JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (07) :543-555

[30] Disease-modifying therapies in relapsing-remitting multiple sclerosis [J].

Gonzalez-Andrade, Fabricio ;

Luis Alcaraz-Alvarez, Jose .

NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 :365-373

← 1 2 3 4 5 →